These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 27884496)

  • 1. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].
    Spasov AA; Chepljaeva NI
    Biomed Khim; 2015; 61(4):488-96. PubMed ID: 26350740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.
    Dahiya L; Kaur R; Kumar R; Kumar M; Palta K
    Curr Diabetes Rev; 2020; 16(4):279-292. PubMed ID: 31057118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
    Freeman JS
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Karras SN; Rapti E; Koufakis T; Kyriazou A; Goulis DG; Kotsa K
    Curr Clin Pharmacol; 2017; 12(4):202-209. PubMed ID: 29473524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
    George C; Byun A; Howard-Thompson A
    Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency.
    Alavi SE; Cabot PJ; Moyle PM
    Mol Pharm; 2019 Jun; 16(6):2278-2295. PubMed ID: 31050435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review.
    Yammine L; Kosten TR; Pimenova M; Schmitz JM
    Diabetes Res Clin Pract; 2019 Mar; 149():78-88. PubMed ID: 30735771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
    Lund A; Knop FK; Vilsbøll T
    Eur J Intern Med; 2014 Jun; 25(5):407-14. PubMed ID: 24694879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The possible synergistic action of sex hormones and glucagon-like peptide-1 (GLP-1) agonists on body mass decline in patients with type 2 diabetes mellitus.
    Režić T; Blaslov K; Kruljac I; Rahelić D; Vrkljan M; Renar IP
    Med Hypotheses; 2019 Oct; 131():109308. PubMed ID: 31443779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis.
    Maciel MG; Beserra BTS; Oliveira FCB; Ribeiro CM; Coelho MS; Neves FAR; Amato AA
    Diabetes Res Clin Pract; 2018 Aug; 142():222-235. PubMed ID: 29857094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.